Cohen Yoram, Rosenbaum Eli, Begum Shahnaz, Goldenberg David, Esche Clemens, Lavie Ofer, Sidransky David, Westra William H
Department of Otolaryngology, Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA.
Clin Cancer Res. 2004 May 15;10(10):3444-7. doi: 10.1158/1078-0432.CCR-03-0562.
An activating point mutation of the BRAF oncogene has been identified in a high proportion of cutaneous nevi and cutaneous melanomas, but its frequency in melanomas arising from the mucosa of head and neck is unknown.
We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay). We also tested 21 cutaneous melanomas, including 13 arising from sun-exposed sites and 8 from a nonsun-exposed site, the vulvar skin.
The 1796T-->A mutation was detected in only 1 (6%) of the sinonasal melanomas. As for cutaneous melanomas, a BRAF mutation was detected in 8 (62%) of the tumors arising in sun-exposed sites but in none (0%) of vulvar melanomas.
In contrast to cutaneous melanomas arising in sun-exposed sites, mucosal melanomas of the head and neck do not frequently harbor an activating mutation of BRAF. This finding additionally supports the view that the various subtypes of melanoma are not equivalent and that distinct genetic alterations may underlie well recognized differences in risk factors and behavioral patterns. Accordingly, patients with melanomas should not be collectively regarded as a uniform group as new strategies are developed that target specific genetic alterations.
在高比例的皮肤痣和皮肤黑色素瘤中已鉴定出BRAF癌基因的激活点突变,但该突变在头颈部黏膜来源的黑色素瘤中的频率尚不清楚。
我们采用直接测序法和一种新开发的使用新型引物延伸方法的检测方法(Mutector检测法),对头颈部17例恶性黏膜黑色素瘤进行BRAF基因第1796位核苷酸胸腺嘧啶(T)到腺嘌呤(A)的错义突变检测。我们还检测了21例皮肤黑色素瘤,其中13例来自阳光暴露部位,8例来自非阳光暴露部位外阴皮肤。
仅在1例(6%)鼻窦黑色素瘤中检测到1796T→A突变。对于皮肤黑色素瘤,在阳光暴露部位发生的肿瘤中有8例(62%)检测到BRAF突变,但外阴黑色素瘤中无一例(0%)检测到。
与阳光暴露部位发生的皮肤黑色素瘤不同,头颈部黏膜黑色素瘤并不经常携带BRAF激活突变。这一发现进一步支持了黑色素瘤的各种亚型并不等同的观点,以及不同的基因改变可能是公认的危险因素和行为模式差异的基础。因此,随着针对特定基因改变的新策略的开发,黑色素瘤患者不应被一概而论地视为一个统一的群体。